8-K: Accuray Reports FY26 Results Amidst Revenue Decline

Accuray Incorporated announced fourth quarter and fiscal year 2026 financial results, highlighting over $20 million in cost improvements and a new financing transaction, but also reporting a significant decrease in total net revenue and product revenue.

Summary

• Accuray reported fourth quarter fiscal 2026 total net revenue of $100.9 million, a 21% decrease year-over-year, with product revenue down 42% to $40.8 million and service revenue up 6% to $60.1 million.
• For the full fiscal year 2026, total net revenue was $401.9 million, a 12% decrease, with product revenue down 27% to $172.7 million and service revenue up 4% to $229.2 million.
• The company achieved over $20 million in cost and margin improvements in fiscal 2026, exceeding its target of $12 million.
• A comprehensive financing transaction with TCW Asset Management was announced to strengthen liquidity, reduce leverage, and provide covenant relief.
• Gross product orders for Q4 FY26 were $37.7 million, a significant drop from $84.7 million in the prior year's quarter, leading to a book-to-bill ratio of 0.9.
• Full-year fiscal 2026 gross product orders were $191.9 million, down from $288.0 million in the prior year, with a book-to-bill ratio of 1.1.
• Order backlog as of June 30, 2026, was $312.5 million, a 27% decrease from the prior fiscal year-end.
• The company reported a net loss of $1.9 million ($0.02 per share) for Q4 FY26, compared to a net income of $1.1 million ($0.01 per share) in the prior year's quarter.
• Full-year fiscal 2026 GAAP net loss was $49.2 million ($0.40 per share), compared to a net loss of $1.6 million ($0.02 per share) in the prior fiscal year.
• Adjusted EBITDA for Q4 FY26 was $12.9 million, an increase from $9.4 million in the prior year's quarter.
• Full-year fiscal 2026 Adjusted EBITDA was $10.6 million, a decrease from $28.3 million in the prior fiscal year.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed to negative sentiment. While cost improvements and a financing deal are positive, significant revenue and order declines, alongside a net loss, indicate substantial challenges.

Positives

• The transformation plan delivered over $20 million in cost and margin improvements in fiscal 2026, significantly exceeding the $12 million target.
• A comprehensive financing transaction with TCW Asset Management was completed, strengthening liquidity, reducing leverage, and enhancing financial flexibility.
• Service revenue increased 6% year-over-year in the fourth quarter and 4% for the full fiscal year, indicating a stable recurring revenue base.
• Gross profit margin improved in the fourth quarter of fiscal 2026 to 34.8% from 30.6% in the prior year's quarter.
• Operating expenses decreased by 15% in the fourth quarter of fiscal 2026, and by 1% for the full fiscal year (excluding restructuring charges, the decrease was 17% and 13% respectively).
• Adjusted EBITDA for the fourth quarter of fiscal 2026 increased to $12.9 million from $9.4 million in the prior year's quarter.
• Total cash, cash equivalents, and short-term restricted cash increased by $2.7 million from March 31, 2026, to $41.2 million as of June 30, 2026.

Negatives

• Total net revenue for the fourth quarter of fiscal 2026 decreased by 21% to $100.9 million compared to $127.5 million in the prior year.
• Product revenue for the fourth quarter of fiscal 2026 decreased by 42% to $40.8 million compared to $70.7 million in the prior year.
• Total net revenue for fiscal year 2026 decreased by 12% to $401.9 million compared to $458.5 million in the prior year.
• Product revenue for fiscal year 2026 decreased by 27% to $172.7 million compared to $237.6 million in the prior year.
• Gross product orders for the fourth quarter of fiscal 2026 were $37.7 million, a significant decrease from $84.7 million in the prior year's quarter.
• Gross product orders for fiscal year 2026 were $191.9 million, a decrease from $288.0 million in the prior fiscal year.
• The book to bill ratio for the fourth quarter of fiscal 2026 was 0.9, down from 1.2 in the prior year's quarter.
• Order backlog as of June 30, 2026, was $312.5 million, approximately 27% lower than the end of the prior fiscal year.
• The company reported a net loss of $1.9 million ($0.02 per share) for the fourth quarter of fiscal 2026, compared to a net income of $1.1 million ($0.01 per share) in the prior year's quarter.
• The company reported a GAAP net loss of $49.2 million ($0.40 per share) for fiscal year 2026, compared to a net loss of $1.6 million ($0.02 per share) in the prior fiscal year.
• Adjusted EBITDA for fiscal year 2026 decreased to $10.6 million from $28.3 million in the prior fiscal year.

Risks

• Ongoing geopolitical uncertainty, tariff pressures, and market volatility could impact financial results.
• Conditions in China and the Middle East, including armed conflict or political instability, could affect the timing of system installations, customer site readiness, service revenue recognition, and the ability to complete transactions in affected markets.
• The company has substantial outstanding indebtedness and must maintain compliance with financial covenants related to its debt.
• Risks related to the effect of the global macroeconomic environment on the operations of the company and those of its customers and suppliers.
• Disruptions to the supply chain, including increased logistics costs.
• Delays in regulatory approvals or the development or release of new offerings.
• The company's ability to convert backlog to revenue.
• The company's ability to achieve widespread market acceptance of its products.

Future Outlook

The company expects continued growth in service revenue, improved service margins, ongoing operating expense discipline, and continued benefits from transformation initiatives in fiscal 2027. However, due to ongoing geopolitical uncertainty, international trade policy, tariff impacts, conditions in China and the Middle East, and broader macroeconomic factors, formal revenue or Adjusted EBITDA guidance for fiscal 2027 is not being provided at this time. Management believes actions taken in fiscal 2026 have strengthened the business and improved the company's ability to execute and create long-term value.

Management Comments

• Fiscal 2026 was a transformational year for Accuray. Throughout the year, we strengthened our operational foundation, improved accountability and execution, expanded our ecosystem of strategic partnerships, advanced differentiated technology capabilities, and took important steps to enhance our financial position.
• Despite ongoing geopolitical uncertainty, tariff pressures, and market volatility, we remained focused on the factors within our control and successfully executed against the transformation initiatives we introduced earlier in the fiscal year. As a result, Accuray enters fiscal 2027 as a stronger company with greater financial flexibility, and a clear focus on driving sustainable revenue growth, margin expansion, and long-term shareholder value.
• Fiscal 2026 was a year of meaningful operational and structural change. While product demand in certain regions remained impacted by geopolitical developments and tariff uncertainty, we continued to expand service revenue, improve operating efficiency, and execute our transformation initiatives ahead of expectations. We also announced a comprehensive transaction that enhances liquidity and reduces leverage as we enter the next phase of Accuray's transformation.

Industry Context

StockSavvy.ai notes that Accuray operates in the radiation therapy market, a segment of the broader medical device industry. The reported decline in product revenue and orders, while concerning, may be influenced by broader industry trends related to capital equipment purchasing cycles, global economic conditions, and geopolitical factors impacting healthcare spending. The growth in service revenue is a positive indicator of recurring revenue streams, which are generally favored by investors.

Stakeholder Impact

• Shareholders: The significant decline in revenue, widening net loss, and reduced order backlog may negatively impact shareholder value in the short term. However, the successful financing transaction and cost-saving measures could provide a foundation for future recovery.
• Creditors: The financing transaction, which reduces leverage and provides covenant relief, is likely a positive development for creditors, improving the company's ability to service its debt.
• Employees: The focus on operational efficiency and transformation may lead to restructuring charges, but the stated goal of strengthening the company aims for long-term stability.
• Customers: Continued innovation and strategic partnerships are intended to benefit customers by providing advanced radiation therapy solutions.

Next Steps

• Focus on driving sustainable revenue growth, margin expansion, and long-term shareholder value in fiscal 2027.
• Continue to expand the strategic partnership ecosystem.
• Accelerate innovation and focus on core competencies.
• Leverage the financing transaction to support long-term strategic objectives.

Key Dates

Recommendation

The company has made progress on cost controls and secured necessary financing, which are positive steps. However, the significant decline in revenue, orders, and backlog, coupled with a widening net loss, presents substantial headwinds. While the service revenue growth is encouraging, the overall financial performance indicates a need for caution. A 'hold' recommendation reflects the uncertainty and the need to see sustained improvement in core revenue generation and profitability before considering a more positive outlook.

Keywords

Accuray, Radiation Therapy, Oncology, Medical Devices, Financial Results, Revenue, EBITDA, Financing